[December 12, 2017] |
|
Pentasa 2016-2017 U.S. Promotional Report - Research and Markets
The "Pentasa
2016 U.S. Promotional Report" report has been added to Research
and Markets' offering.
The 5 Key Questions Addressed by this Report:
-
How many physicians were reached by Pentasa through personal promotion
in 2016 and how does this compare to its peer set in the Ulcerative
Colitis markets?
-
What promotional mix was leveraged (e.g., sales rep detailing,
physician education, and paid speaking) and what was the median spend
on each type of activity?
-
How does Shire's depth of coverage vary within key specialties (e.g.,
Gastroenterology and Internal Medicine) and how does this compare to
its peers and the overall set of rep-accessible physicans?
-
How often are physicians receiving paid meals for Pentasa throughout
the year (e.g., monthly, quarterly, annually)?
-
Who were the most detailed prescribers and top paid speakers for
Pentasa in 2016?
Data Sources and Methodology:
-
We leverage company-reported financial transaction data disclosed
through CMS Open Payments. This data set captures all transfers of
value (e.g., speaking fees, consulting fees, travel, education, and
meals) made on behalf of a drug or device manufacturer to a physician.
Currently, 42 months of longitudinal data is available - covering
payments to more than 900,000 U.S. healthcare professionals.
-
Over 12,200 paid interactions across 3,500 physicians made on behalf
of Pentasa were carefully examined to support our analysis. In
addition, interaction data from 7 peer products (e.g. Apriso, Entyvio,
Humira, Lialda, Remicade, Simponi, and Uceris ) was leveraged to
provide benchmarking and market insights.
For more information about this report visit https://www.researchandmarkets.com/research/53bgs5/pentasa_20162017?w=4
View source version on businesswire.com: http://www.businesswire.com/news/home/20171212006236/en/
[ Back To TMCnet.com's Homepage ]
|